Age is not just a number when it comes to clinical trials
October 22, 2024 | Age, Diversity, Inclusion, Representation, Trial Design, clinical trials
In this blog we look at the critical underrepresentation of older adults in clinical trials, emphasising the need for inclusive trial designs and targeted strategies to ensure safe and effective medicines for this population.
Age is just a number. You’re as young as you feel.
Right? Well, when it comes to clinical trials, not quite.
Older people (those aged 65 and above) use the largest share of medicines, but are severely underrepresented in clinical trials across most treatment areas.1 This is especially true for the over-75s, who account for as few as 1% of trial participants.2
This has some big implications. It means medicines are coming into use that may not have been fully tested with, by, or for their intended audience.
As an example, less than half of the US Food and Drug Administration (FDA)’s drug approvals include safety and efficacy data from older people.2 This data can’t just be generalised from younger trial participants.1 When it is, HCPs have difficulties prescribing,3 and older people may experience unexpected, serious side effects.1
It’s clear then that greater representation of older people in clinical trials is not just a nice to have, it’s crucial to ensure safe, effective medicines in the real world. Older people do want to take part in clinical trials, and generally have positive experiences when they do.4 But, despite action from the European Commission, FDA1 and UK MHRA5, the problem of low representation still exists.
Why is this?
Eligibility criteria are essential to ensure the safety and accuracy of clinical trials. But many trials feature poorly justified, restrictive criteria, based on arbitrary upper age limits6, comorbidities7, and polypharmacy6, among others, which exclude many older people from taking part. And those who do take part are often fitter, healthier, and less representative of the general population.8
But this is just one part of the equation. Older people who meet all of a trial’s eligibility criteria still face other barriers that younger participants might not. Things like:
- Poorer understanding of the informed consent process1
- Increased risk and burden of side effects1
- Issues with trial site access, and the number and length of visits1
- Simply losing interest if they’re not being appropriately engaged7
So, how can the industry address this?
Through fresh perspectives on how trials are designed and communicated.
If older people are the intended population for a new medicine, involving them, and their loved ones, in trial planning from the start can help to set priorities, remove logistical barriers, and ensure eligibility criteria are fully justified.8
Alternative trial designs may offer effective new ways to involve older people. For example, some adaptive trials have completely removed age restrictions5, and trials featuring expanded-eligibility cohorts may allow the inclusion of more people with comorbidities9. Where appropriate, decentralised trials could also allow treatment, testing, and monitoring from the comfort of home5.
Whatever the design, human interactions are a cornerstone of any successful clinical trial. To engage with older people in clinical trials, they need a network of engaged people around them:
– Familiar faces among site staff, with the skills, time and resources to adapt to their needs1
– Family, friends, and caregivers who understand the trial and can advocate for them8
– A broader community they feel part of, to provide motivation and moral support1
Every part of this network needs targeted strategies, from accessible participant information sheets that help overcome cognitive and sensory barriers, to bespoke support materials for caregivers, to communication training for site staff.
If we can do this right, it’ll mean new medicines, developed with older people, for older people.
References
- Buttgereit, T., ‘Barriers and potential solutions of older patients in clinical trials’, Oxford Academic, Age and Ageing, Vol. 50, Issue 6. Accessed August 2024. Available here.
- Van Marum, J., ‘Underrepresentation of the elderly in clinical trials’, British Pharmacological Society, Vol. 86, Issue 10. Accessed August 2024. Available here.
- Schwartz, B., ‘Representative enrolment of older adults in clinical trials’, The Lancet, Healthy Longevity, Vol. 4, Issue 7. Accessed August 2024. Available here.
- Parks, M., ‘Current Challenges Faced by Cancer Clinical Trials’, Springer Link, Oncology and Therapy, Vol. 9, pages 55 – 67. Accessed August 2024. Available here.
- Walker, E., ‘The status of drug evaluation in older adults in the United Kingdom’, Journal of the American Geriatrics Society. Accessed August 2024. Available here.
- Cruz-Jentoft, J., ‘Upper age limits in studies submitted to a research ethics committee’, National Library of Medicine. Accessed August 2024. Available here.
- Forsat, D., ‘Recruitment and Retention of Older People in Clinical Research’, Journal of the American Geriatrics Society. Accessed August 2024. Available here.
- Pitkala, H., ‘Clinical trials in older people’, Oxford Academic, Age and Ageing, Vol. 51, Issue 5. Accessed August 2024. Available here.
- Jin, S., ‘Re-Evaluating Eligibility Criteria for Oncology Clinical Trials’, National Library of Medicine, Journal of Clinical Oncology. Accessed August 2024. Available here.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
It’s time to stop calling adverse events ‘manageable’
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
The solution: Good localisation doesn’t feel translated
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Healthcare information is becoming easier to access. Trust isn’t.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.
Where translation falls short in practice
Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.
Where it all began – why we developed The Experience Gap
Learn how The Experience Gap was developed to help sponsors, CROs and site teams improve clinical trial participation by identifying friction points, enhancing patient experience, and driving better recruitment and...
Cuttsy+Cuttsy launches a practical roadmap to enhance clinical trial participant experience
Cuttsy+Cuttsy has launched The Experience Gap, a practical roadmap designed to help clinical trial teams improve participant engagement, support and retention across the full study journey.
Cuttsy+Cuttsy welcomes three new experts to the team
Cuttsy+Cuttsy is happy to be welcoming three new people to the team this month.